FULC - Fulcrum upgraded to buy at Stifel on ending of clinical hold
2023-08-22 11:56:20 ET
More on Fulcrum Therapeutics
- Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD
- Fulcrum inks licensing deal for rare blood disorder
- Fulcrum slips as Goldman Sachs downgrades on limited catalyst path
- Seeking Alpha’s Quant Rating on Fulcrum Therapeutics
For further details see:
Fulcrum upgraded to buy at Stifel on ending of clinical hold